Characterization of the brain β-amyloid isoform pattern at different ages of Tg2576 mice

Neurodegenerative Diseases

Volumn 8, Issue 5, 2011, Pages 352-363

  Mustafiz, Tamanna ^a   Portelius, Erik ^b   Gustavsson, Mikael K ^b   Hölttä, Mikko ^b   Zetterberg, Henrik ^b   Blennow, Kaj ^b   Nordberg, Agneta ^a   Unger Lithner, Christina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Amyloid; A oligomers; Alzheimer's disease; Tau; Tg2576 mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-16]; AMYLOID BETA PROTEIN[1-17]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; EPITOPE; GLYCOGEN SYNTHASE KINASE 3BETA; ISOPROTEIN; OLIGOMER; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; FEMALE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; BRAIN CHEMISTRY; CEREBRAL CORTEX; MALE; MICE; MICE, TRANSGENIC; PROTEIN ISOFORMS; PROTEIN PRECURSORS;

EID: 79958778139     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000323871     Document Type: Article

References (41)

1. Roher A, Wolfe D, Palutke M, KuKuruga D: Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA 1986;83:2662-2666. (Pubitemid 16026943)
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913-4917.
3. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356. (Pubitemid 34790756)
4. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539. (Pubitemid 34288854)
5. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric a beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003;100:10417-10422. (Pubitemid 37071893)
6. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-357.
7. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H: Globular amyloid betapeptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005;95:834-847. (Pubitemid 41567174)
8. Harper JD, Wong SS, Lieber CM, Lansbury PT: Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997;4:119-125. (Pubitemid 27161750)
9. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX: Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005;22:1942-1950. (Pubitemid 41579384)
10. Iqbal K, Zaidi T, Bancher C, Grundke-Iqbal I: Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett 1994;349:104-108.
11. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A: Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001;60:1190-1197. (Pubitemid 33117099)
12. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.
13. Ferrer I, Pastor P, Rey MJ, Munoz E, Puig B, Pastor E, Oliva R, Tolosa E: Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. Neuropathol Appl Neurobiol 2003;29:23-34. (Pubitemid 36238114)
14. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
15. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT: Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997;17:7053-7059. (Pubitemid 27427884)
16. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH: The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002;22:1858-1867. (Pubitemid 35386304)
17. Unger C, Hedberg MM, Mustafiz T, Svedberg MM, Nordberg A: Early changes in Abeta levels in the brain of APPswe transgenic mice - implication on synaptic density, alpha7 neuronal nicotinic acetylcholineand N-methyl-D-aspartate receptor levels. Mol Cell Neurosci 2005;30:218-227. (Pubitemid 41316564)
18. Portelius E, Zhang B, Gustavsson MK, Brinkmalm G, Westman-Brinkmalm A, Zetterberg H, Lee VM, Trojanowski JQ, Blennow K: Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. Neurodegener Dis 2009;6:258-262.
19. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
20. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC: Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 2001;158:1173-1177. (Pubitemid 32221809)
21. Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, Gonzalez MI: Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 2004;1017:130-136. (Pubitemid 38917152)
22. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ: Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 1999;103:145-162. (Pubitemid 29417998)
23. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A: Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007;6:4433-4439. (Pubitemid 350158518)
24. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL: Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23-35. (Pubitemid 46085837)
25. Ikeuchi T, Kaneko H, Miyashita A, Nozaki H, Kasuga K, Tsukie T, Tsuchiya M, Imamura T, Ishizu H, Aoki K, Ishikawa A, Onodera O, Kuwano R, Nishizawa M: Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement Geriatr Cogn Disord 2008;26:43-49.
26. Hedberg MM, Svedberg MM, Mustafiz T, Yu WF, Mousavi M, Guan ZZ, Unger C, Nordberg A: Transgenic mice overexpressing human acetylcholinesterase and the Swedish amyloid precursor protein mutation: effect of nicotine treatment. Neuroscience 2008;152:223-233.
27. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
28. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234. (Pubitemid 43238346)
29. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL:Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
30. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577. (Pubitemid 30161512)
31. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT: Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 2010;30:2442-2453.
32. Ballatore C, Lee VM, Trojanowski JQ: Taumediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663-672. (Pubitemid 47283144)
33. Guo JP, Arai T, Miklossy J, McGeer PL:Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:1953-1958. (Pubitemid 43228799)
34. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, Van Leuven F: Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 2008;172:786-798. (Pubitemid 351354550)
35. Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX: Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 2007;26:3429-3436. (Pubitemid 350243526)
36. Wang JZ, Grundke-Iqbal I, Iqbal K:Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007;25:59-68. (Pubitemid 46098893)
37. Mattsson N, Savman K, Osterlundh G, Blennow K, Zetterberg H: Converging molecular pathways in human neural development and degeneration. Neurosci Res 2010;66:330-332.
38. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR: Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993;12:803-808. (Pubitemid 23073729)
39. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR: Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1992;1114:147-162. (Pubitemid 23008367)
40. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH: p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998;273:24057-24064. (Pubitemid 28435748)
41. Cruz JC, Tsai LH: Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 2004;10:452-458. (Pubitemid 39209212)